In one paragraphArticle in PNAS nexus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Enrico M NovelliPittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Division of Classical Hematology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.ORCID https://orcid.org/0000-0003-3010-8285 Shane C LenhartPittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Division of Classical Hematology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.ORCID https://orcid.org/0009-0001-2595-9379 Nandinii SekarPittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Division of Classical Hematology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.ORCID https://orcid.org/0009-0008-2827-3138 Paritosh MondalPittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Division of Classical Hematology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.ORCID https://orcid.org/0000-0002-2608-6645 T Kevin HitchensAdvanced Imaging Center, Department of Neurobiology, University of Pittsburgh, Pittsburgh, PA 15203, USA.
Samit GhoshPittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Division of Classical Hematology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.ORCID https://orcid.org/0000-0002-3536-3077 Stephen Y ChanPittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Division of Classical Hematology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.ORCID https://orcid.org/0000-0002-9520-7527 Rimi HazraPittsburgh Heart, Lung, and Blood Vascular Medicine Institute and Division of Classical Hematology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.ORCID https://orcid.org/0000-0003-2390-0071 Funding
Defining the Complex Biology of the miR-130/301 Family in Pulmonary HypertensionR01HL124021 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHAN, STEPHEN Y · 2014 to 2025
$4.9MIron-Sulfur Deficiency as a Critical Pathogenic Cause of Pulmonary HypertensionR01HL122596 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHAN, STEPHEN Y · 2015 to 2024
$4.5MGenetic and hypoxic control of a lncRNA axis orchestrates endothelial reprogramming in pulmonary hypertensionR01HL151228 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Stephen Y Chan · 2023 to 2026
$2.8MRenal endothelium and the development of chronic kidney disease in sickle cell disordersR01DK132145 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Samit Ghosh · 2023 to 2026
$2.5MMolecular and Cellular Pathogenesis of Kidney Disease in Sickle Cell DisordersR01DK124426 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GHOSH, SAMIT · 2021 to 2024
$1.4MNeurovascular frataxin and cognitive dysfunction in sickle cell diseaseR21NS131634 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HAZRA, RIMI · 2023 to 2024
$430kNHLBI NIH HHS R01 HL122596NHLBI NIH HHS R01 HL124021NHLBI NIH HHS R01 HL151228NIDDK NIH HHS R01 DK124426NIDDK NIH HHS R01 DK132145NINDS NIH HHS R21 NS131634
6 · The paper itselfAbstract
Individuals with sickle cell disease (SCD) suffer from a high burden of neurocognitive impairment. Cerebrovascular lesions, characterized by diffusion tensor imaging identified neuroaxonal damage, are associated with learning and memory deficits. The molecular and cellular intermediates driving microstructural neuroaxonal damage and cognitive impairment in SCD remain largely unexplored. Herein, we report that sickle cell mice (SS) have reduced expression of frataxin (FXN), a mitochondrial protein, in their astrocytes compared with normal control (AA) mice. A newly generated sickle bone marrow chimeric mouse with astrocyte-specific deletion of FXN (SS
Indexed as
frataxinneurocognitionsickle cell disease
Identifiers
PMID42037666
PMCPMC13108596
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390